Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

← catalyst calendar

NCT06559176 · readout ≤ 1,261 d

Sponsored by Prime Medicine, Inc. (industry) · PRME — their whole pipeline →.

Phase
Phase 1/2
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
12estimated
Sites
5
Countries
Canada, United Kingdom, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-10-17actualWhen the study began enrolling
Primary completionJan 2030estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionFeb 2030estimatedThe whole study's end, after follow-up
First posted2024-08-19actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-04-06actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Chronic Granulomatous Disease
  • Granulomatous Disease, Chronic

Intervention

  • Biological: PM359

Primary outcomes

what the primary-completion date above is the date OF
Safety of administration of PM359, as quantified by frequency of adverse events (AEs) after drug product infusion
measured PM359 infusion through Month 12 after PM359 infusion
Percentage of participants with sustained reconstitution of NADPH oxidase activity in neutrophils
measured At Month 6 and Month 12 after PM359 infusion, as compared to baseline

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PRME's whole pipeline · Catalyst calendar · Every registered study · What changed